Research programme: cancer therapeutics - Foghorn Therapeutics/ Lilly Research Centre
Latest Information Update: 30 Dec 2021
At a glance
- Originator Foghorn Therapeutics; Lilly Research Centre
- Class Antineoplastics
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer